{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:35:18Z","timestamp":1788183318673,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33\u2009+\u2009AML in adults and children \u2265\u20091\u00a0month old, and relapsed or refractory CD33\u2009+\u2009AML in adults and children \u2265\u20092\u00a0years old. GO treatment has been associated with an increased risk of hepatotoxicity and hepatic veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS), especially following hematopoietic stem cell transplantation. Other non-specific serious adverse events (SAEs) associated with GO treatment are myelosuppression, bleeding\/thrombocytopenia, infusion-related reaction, and tumor lysis syndrome. This report summarizes an expert panel of physicians\u2019 recommendations for the evaluation and management of SAEs following GO, emphasizing the prevention and management of VOD\/SOS.<\/jats:p>","DOI":"10.1186\/s13045-020-00975-2","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T08:03:12Z","timestamp":1602748992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge E.","family":"Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dombret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elihu H.","family":"Estey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"issue":"4","key":"975_CR1","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1172\/JCI112932","volume":"79","author":"ID Bernstein","year":"1987","unstructured":"Bernstein ID, Singer JW, Andrews RG, Keating A, Powell JS, Bjornson BH, Cuttner J, Najfeld V, Reaman G, Raskind W, et al. Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. J Clin Invest. 1987;79(4):1153\u20139.","journal-title":"J Clin Invest"},{"issue":"4","key":"975_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/0145-2126(84)90001-8","volume":"8","author":"JD Griffin","year":"1984","unstructured":"Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984;8(4):521\u201334.","journal-title":"Leuk Res"},{"issue":"3","key":"975_CR3","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1182\/blood.V96.3.870","volume":"96","author":"O Legrand","year":"2000","unstructured":"Legrand O, Perrot JY, Baudard M, Cordier A, Lautier R, Simonin G, Zittoun R, Casadevall N, Marie JP. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood. 2000;96(3):870\u20137.","journal-title":"Blood"},{"issue":"6","key":"975_CR4","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490\u20136.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"975_CR5","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","volume":"121","author":"SH Petersdorf","year":"2013","unstructured":"Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, Larson RA, Erba HP, Stiff PJ, Stuart RK, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854\u201360.","journal-title":"Blood"},{"issue":"9825","key":"975_CR6","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508\u201316.","journal-title":"Lancet"},{"issue":"9","key":"975_CR7","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","volume":"34","author":"S Amadori","year":"2016","unstructured":"Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, Annino L, Venditti A, Voso MT, Mazzone C, et al. Gemtuzumab Ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol. 2016;34(9):972\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"975_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/sj.leu.2404434","volume":"21","author":"AL Taksin","year":"2007","unstructured":"Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, Bouabdallah R, Pautas C, Turlure P, Reman O, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21(1):66\u201371.","journal-title":"Leukemia"},{"key":"975_CR9","doi-asserted-by":"crossref","unstructured":"Delaunay J, Recher C, Pigneux A, Witz F, Vey N, Blanchet O, Lefebvre P, Luquet I, Guillerme I, Volteau C, et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR Study. Blood. 2011;118(21):79.","DOI":"10.1182\/blood.V118.21.79.79"},{"issue":"4","key":"975_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, Yin JA, Hunter A, Goldstone AH, Wheatley K. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369\u201377.","journal-title":"J Clin Oncol"},{"issue":"32","key":"975_CR11","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","volume":"30","author":"AK Burnett","year":"2012","unstructured":"Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, Hunter AE, Yin J, Craddock CF, Dufva IH, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30(32):3924\u201331.","journal-title":"J Clin Oncol"},{"issue":"1","key":"975_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","volume":"104","author":"J Lambert","year":"2019","unstructured":"Lambert J, Pautas C, Terre C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104(1):113\u20139.","journal-title":"Haematologica"},{"issue":"5","key":"975_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/cpt.1500","volume":"106","author":"LK Fostvedt","year":"2019","unstructured":"Fostvedt LK, Hibma JE, Masters JC, Vandendries E, Ruiz-Garcia A. Pharmacokinetic\/pharmacodynamic modeling to support the re-approval of gemtuzumab ozogamicin. Clin Pharmacol Ther. 2019;106(5):1006\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"975_CR14","unstructured":"Mylotarg (gemtuzumab ozogamicin) [prescribing information]. 2017."},{"key":"975_CR15","unstructured":"US Food and Drug Administration (FDA). Mylotarg (gemtuzumab ozogamicin) [prescribing information] https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761060s004lbl.pdf."},{"key":"975_CR16","unstructured":"European Medical Agency. Committee for Medicinal Products for Human Use (CHMP): Assessment Report (Mylotarg). 2018."},{"issue":"5","key":"975_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1034\/j.1600-0609.2000.9r200.x","volume":"64","author":"E Carreras","year":"2000","unstructured":"Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol. 2000;64(5):281\u201391.","journal-title":"Eur J Haematol"},{"issue":"12","key":"975_CR18","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bmt.2011.65","volume":"46","author":"E Carreras","year":"2011","unstructured":"Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant. 2011;46(12):1495\u2013502.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"975_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, Guinan E, Vogelsang G, Krishnan A, Giralt S, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157\u201368.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"975_CR20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/sj.bmt.1701994","volume":"24","author":"HC Toh","year":"1999","unstructured":"Toh HC, McAfee SL, Sackstein R, Cox BF, Colby C, Spitzer TR. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant. 1999;24(8):891\u20135.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"975_CR21","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Bazarbachi A, et al. Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50(6):781\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"975_CR22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","volume":"31","author":"JM McKoy","year":"2007","unstructured":"McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, Kuzel TM, Trifilio SM, Raisch DW, Kell J, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31(5):599\u2013604.","journal-title":"Leuk Res"},{"issue":"7","key":"975_CR23","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","volume":"99","author":"P Rajvanshi","year":"2002","unstructured":"Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99(7):2310\u20134.","journal-title":"Blood"},{"issue":"Suppl 1","key":"975_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2018-99-111251","volume":"132","author":"C Pautas","year":"2018","unstructured":"Pautas C, Raffoux E, Lambert J, Legrand O, Benner RJ, Vandendries ER, Gogat K, Dombret H, Castaigne S. Outcomes following hematopoietic stem cell transplantation in patients treated with chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia. Blood. 2018;132(Suppl 1):28\u201328.","journal-title":"Blood"},{"issue":"2","key":"975_CR25","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/sj.leu.2405014","volume":"22","author":"M de Lima","year":"2008","unstructured":"de Lima M, Champlin RE, Thall PF, Wang X, Martin TG 3rd, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, et al. Phase I\/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008;22(2):258\u201364.","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"975_CR26","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1182\/blood-2018-99-110804","volume":"132","author":"ES Wang","year":"2018","unstructured":"Wang ES, Aplenc R, Chirnomas D, Dugan MJ, Fazal S, Iyer S, Lin TL, Nand S, Pierce KJ, Shami PJ, et al. Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. Blood. 2018;132(Suppl 1):3979\u20133979.","journal-title":"Blood"},{"issue":"5","key":"975_CR27","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.bbmt.2019.12.763","volume":"26","author":"VT Ho","year":"2019","unstructured":"Ho VT, St Martin A, Perez WS, Steinert P, Zhang MJ, Chirnomas D, Hoang CJ, Loberiza FR Jr, Saber W. Prior gemtuzumab ozogamicin exposure in adults with acute myeloid leukemia does not increase hepatic veno-occlusive disease risk after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant. 2019;26(5):884\u201392.","journal-title":"Biol Blood Marrow Transplant"},{"key":"975_CR28","unstructured":"Defitelio (defibrotide sodium) [prescribing information]. 2016."},{"issue":"3","key":"975_CR29","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","volume":"22","author":"JH Dalle","year":"2016","unstructured":"Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016;22(3):400\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"975_CR30","doi-asserted-by":"publisher","unstructured":"Genthon A, Brissot E, Malard F, van de Wyngaert Z, Bonnin A, Banet A, Marjanovic Z, Ikhlef S, Lapusan S, Sestili S, et al. Gemtuzumab Ozogamicin Combined with intensive chemotherapy in patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2020;S2152-2650(20):30331-1.\nhttps:\/\/doi.org\/10.1016\/j.clml.2020.07.001.","DOI":"10.1016\/j.clml.2020.07.001"},{"key":"975_CR31","doi-asserted-by":"crossref","unstructured":"Cheuk DK, Chiang AK, Ha SY, Chan GC. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2015(5):CD009311.","DOI":"10.1002\/14651858.CD009311.pub2"},{"key":"975_CR32","doi-asserted-by":"crossref","unstructured":"Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A, Veys P, Potter MN, Haemato-oncology Task Force of British Committee for Standards in H, British Society for B, et al. BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013;163(4):444\u201357.","DOI":"10.1111\/bjh.12558"},{"issue":"3","key":"975_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41408-020-0286-5","volume":"10","author":"PG Richardson","year":"2020","unstructured":"Richardson PG, Corbacioglu S. Veno-occlusive disease\/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. Blood Cancer J. 2020;10(3):29.","journal-title":"Blood Cancer J"},{"issue":"13","key":"975_CR34","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","volume":"19","author":"EL Sievers","year":"2001","unstructured":"Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244\u201354.","journal-title":"J Clin Oncol"},{"issue":"2","key":"975_CR35","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1188\/10.CJON.E10-E21","volume":"14","author":"WH Vogel","year":"2010","unstructured":"Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14(2):E10-21.","journal-title":"Clin J Oncol Nurs"},{"issue":"2","key":"975_CR36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5492\/wjccm.v4.i2.130","volume":"4","author":"AE Mirrakhimov","year":"2015","unstructured":"Mirrakhimov AE, Voore P, Khan M, Ali AM. Tumor lysis syndrome: a clinical review. World J Crit Care Med. 2015;4(2):130\u20138.","journal-title":"World J Crit Care Med"},{"issue":"1","key":"975_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3324\/haematol.11575","volume":"93","author":"P Montesinos","year":"2008","unstructured":"Montesinos P, Lorenzo I, Martin G, Sanz J, Perez-Sirvent ML, Martinez D, Orti G, Algarra L, Martinez J, Moscardo F, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93(1):67\u201374.","journal-title":"Haematologica"},{"issue":"7","key":"975_CR38","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Bazarbachi A, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906\u201312.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"975_CR39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bmt.2017.161","volume":"53","author":"S Corbacioglu","year":"2018","unstructured":"Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, Dignan F, Gibson B, Guengoer T, Gruhn B, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018;53(2):138\u201345.","journal-title":"Bone Marrow Transplant"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00975-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-020-00975-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00975-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T23:20:18Z","timestamp":1634253618000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-00975-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["975"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-00975-2","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"12 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jorge E. Cortes received research funding to his institution and consulting honoraria from Pfizer, Novartis, Astellas, Daiichi Sankyo, Jazz Pharmaceuticals, Takeda, and Celgene. Marcos de Lima was a consultant and served on advisory boards for Celgene, Incyte, Kiadis Pharma, Partner Therapeutics, Pfizer, and Pharmacyclics. Herv\u00e9 Dombret, Elihu H. Estey, and Sergio A. Giralt have no conflicts of interest to declare. Pau Montesinos was a consultant and served on advisory boards for AbbVie, Agios, Astellas, Celgene, Daiichi Sankyo, Incyte, Janssen, Karyopharm, Novartis, Oryzon, Pfizer, Teva, and Tolero, and received research funding to his institution from Astellas, Celgene, Daiichi Sankyo, Janssen, Karyopharm, Novartis, Pfizer, and Teva. Christoph R\u00f6llig received research funding to his institution and consulting honoraria from AbbVie, Amgen, Astellas, Bayer, BMS, Celgene, Daiichi Sankyo, Janssen, Jazz, Novartis, Pfizer, Roche, and Takeda. Adriano Venditti was a consultant and served on advisory boards for Novartis, Pfizer, Astellas, and Daiichi Sankyo. Eunice S. Wang has received consultancy fees from Abbvie, Amgen, Astellas, Daiichi Sankyo, Genentech, Jazz, Kite Pharmaceuticals, Kura Oncology, Macrogenics, Pfizer, PTC Therapeutics, and Stemline, and has served as a speaker for Dava Oncology and Stemline, Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}